Angelini, a leading Italian pharmaceutical company, has started the promotion and marketing of a new active wound cleanser in Italian hospitals and wound therapy centres. The innovative acid-oxidizing solution contains hypoclorous acid and is indicated for the treatment of chronic wounds.
The product has been acquired based on an exclusive partnership between Angelini and the Swiss company APR Applied Pharma Research, the owner and developer of the proprietary, patented technology TEHCLO, which enables the production of this acidic and super-oxidizing solution. This solution creates an unfavorable environment for the growth of microorganisms and may favor the release of oxygen in the injured tissues. The new acid-oxidizing wound cleanser solution is indicated for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds like diabetic foot ulcers, pressure ulcers, lower legs ulcers and vascular ulcers.
In the field of wound care, Angelini is now able to provide healthcare professionals with a range of wound treatment options from active cleansing, to antisepsis and epithelialization support.
“With the launch of this product, Angelini aims at strengthening its position in the Wound Care therapeutic area fulfilling a medical need of the scientific community, which encompasses the shift from a passive method of mere cleansing to an active process supporting the physiological healing process.” stated Fabio De Luca, chief commercial officer Italy of Angelini Pharma Division.
Paolo Galfetti, chief executive officer of APR said, “We are very proud to see this product on the Italian market as it represents a new and unique option to actively cleanse any kind of wound. While cleansing the wound bed, this innovative product is able to modulate the lesion’s microenvironment contributing to the control of the microbial burden, protecting from the risk of local infection, as well as sustaining physiological healing. We believe that this product, for its adaptable use along the continuum of wound care, offers the opportunity to exploit the growth forecasted in the wound cleansing market on an European basis, which is expected to hit a total value of $220 Mio in 2019.”
The new acid-oxidizing solution has been developed based on APR’s proprietary patented technology TEHCLO, enabling the production of an acidic and super-oxidizing solution characterized by pH<3, RedOx >1000mV and stabilized hypochlorous acid (>95 per cent of free chlorine species).
It is intended for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, lower leg ulcers, vascular ulcers), post-surgical wounds, cuts, abrasions, burns and other lesions. As it contains hypochlorous acid as a preservative, it can prevent wound contamination by exerting a local antimicrobial effect on the wound surface. The convenient and easy-to-use spray formulation completes the product’s profile, providing healthcare professionals with a new tool for an optimized wound care.
The product is certified in EU as Class III Medical Device according to the rigorous European regulation.